BGB-16673 is an investigational new drug that is being evaluated by BeOne Medicines for the treatment of relapsed and refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and other lymphomas. BGB-16673 is a proteolysis targeting chimera (PROTAC) that acts by using the ubiquitin-proteasome system to target Bruton's tyrosine kinase (BTK) for degradation.
References